This Stock Is Available With A Massive Dividend Of Rs 377 per Share, Should You Buy?


This Stock Is Available With A Massive Dividend Of Rs 377 per Share, Should You Buy?

Shares To Buy

Sanofi India has declared a very robust dividend. The company has declared a final dividend of 1940%, while the special dividend is 1830%. This takes the total dividend to about 3770% or Rs 377 per share, considering the face value of Rs 10.

 Stock

Dividend details of Sanofi India

The shares of the company go ex dividend on April 28, 2023, which means one needs to buy the stock before that to receive dividends. Please note, that dividends are taxable in the hands of investors and investors should decided accordingly, especially if you are in the highest tax bracket.

Should you buy the stock of Sanofi India

Sharekhan had a buy call on the stock of Sanofi India with a price target of Rs 6200 on the stock, which is higher than the current market price of Rs 5750. Those buying the stock would receive the dividend of Rs 377 per share, which means your cost of acquisition would reduce. The shares of Sanofi have hit a 52-week high of Rs 7938 and a 52-week low of Rs 5240.

The company is a MNC that is in the pharma business. Sanofi, is one of the world’s leading healthcare companies, and its 100% subsidiary – Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.4% of its paid-up share capital. Sanofi India offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines. The products manufactured by the Company are distributed in India and exported to many developed as well as developing countries.

The company has performed very well over the last few years and we believe that it would continue to give good dividend yields.

Disclaimer

We would like to emphasize that the article is for information purposes only and should not be construed as investment ideas. The buy call is from the stock report of Sharekhan. Greynium Information Technologies, the Author and Sharekhan are not liable for any losses caused as a result of decisions based on the article. Goodreturns.in advises users to consult with certified experts before making any investment decision.





Source link

Scroll to Top